Company news

Arbutus Biopharma Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

October 1, 2026

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

September 30, 2026

Arbutus Biopharma Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

August 24, 2026

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

August 21, 2026

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

July 16, 2026

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

April 14, 2026

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

March 22, 2026

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

March 3, 2026

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

October 6, 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

June 24, 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 6, 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

April 22, 2025

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

March 26, 2025

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 2, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

February 25, 2025

Arbutus Provides 2025 Corporate and Financial Update

January 12, 2025

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

November 25, 2024

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

November 14, 2024

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

November 14, 2024

Arbutus to Present at Jefferies London Healthcare Conference

November 13, 2024

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2024

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

October 22, 2024

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

October 14, 2024

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

September 30, 2024

Arbutus to Participate in Two Upcoming Investor Conferences

September 2, 2024

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

July 31, 2024

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

July 17, 2024

Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

June 5, 2024

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

June 5, 2024

Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

June 4, 2024

Arbutus to Participate in Jefferies Global Healthcare Conference

May 28, 2024

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 21, 2024

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 1, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

April 17, 2024

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

April 3, 2024

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

February 28, 2024

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

February 14, 2024

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

January 7, 2024

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

November 8, 2023

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

November 6, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

October 23, 2023

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

October 17, 2023

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

October 10, 2023

Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.